First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Stock Short Interest Rises 629.8%

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 69,113 shares, a growth of 629.8% from the September 30th total of 9,470 shares. Based on an average daily trading volume, of 175,224 shares, the short-interest ratio is presently 0.4 days. Currently, 0.3% of the shares of the company are sold short.

First Trust Nasdaq Pharmaceuticals ETF Stock Performance

Shares of FTXH traded up $0.15 during mid-day trading on Wednesday, hitting $43.27. 131,722 shares of the company were exchanged, compared to its average volume of 226,011. The company has a 50 day moving average of $41.55 and a 200-day moving average of $37.04. First Trust Nasdaq Pharmaceuticals ETF has a 1-year low of $29.40 and a 1-year high of $43.52. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 14.51 and a beta of 0.45.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Thursday, September 24th were given a dividend of $0.0113 per share. This is a drop from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.0920. This represents a $0.05 annualized dividend and a dividend yield of 0.1%. The ex-dividend date of this dividend was Thursday, September 24th.

Institutional Investors Weigh In On First Trust Nasdaq Pharmaceuticals ETF

Large investors have recently modified their holdings of the company. Compass Financial Management LLC acquired a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the 2nd quarter valued at about $29,000. Nilsine Partners LLC increased its holdings in First Trust Nasdaq Pharmaceuticals ETF by 3.5% in the second quarter. Nilsine Partners LLC now owns 28,057 shares of the company’s stock valued at $1,071,000 after buying an additional 937 shares in the last quarter. Vivaldi Capital Management LP boosted its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 16.0% in the 1st quarter. Vivaldi Capital Management LP now owns 12,590 shares of the company’s stock worth $433,000 after buying an additional 1,741 shares in the last quarter. Flagship Harbor Advisors LLC raised its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 50.9% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 8,500 shares of the company’s stock worth $352,000 after purchasing an additional 2,868 shares during the last quarter. Finally, Englebert Financial Advisers LLC acquired a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF during the third quarter valued at $751,000.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.